http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 14 Oct 2026 16:05:23 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html <p>Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced the appointment of Jeffrey Farrow to its board of directors, effective October 13, 2026, expanding the board from seven to eight members.</p> <p>Farrow fills a newly created Class III director seat, appointed upon the recommendation of the Nominating and Corporate Governance Committee. He will also serve on the Audit Committee. The board has determined that Farrow qualifies as independent under Nasdaq listing rules.</p> <p>Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS). He also sits on the boards of Clover Biopharmaceuticals, Ltd. (HKEX) and Achieve Life Sciences, Inc. http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html Wed, 14 Oct 2026 16:05:23 -0400 ACHV LSTA TARS http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html <p>Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced the appointment of Jeffrey Farrow to its board of directors, effective October 13, 2026, expanding the board from seven to eight members.</p> <p>Farrow fills a newly created Class III director seat, appointed upon the recommendation of the Nominating and Corporate Governance Committee. He will also serve on the Audit Committee. The board has determined that Farrow qualifies as independent under Nasdaq listing rules.</p> <p>Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS). He also sits on the boards of Clover Biopharmaceuticals, Ltd. (HKEX) and Achieve Life Sciences, Inc. http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html Wed, 14 Oct 2026 16:05:23 -0400 ACHV LSTA TARS http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html <p>Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced the appointment of Jeffrey Farrow to its board of directors, effective October 13, 2026, expanding the board from seven to eight members.</p> <p>Farrow fills a newly created Class III director seat, appointed upon the recommendation of the Nominating and Corporate Governance Committee. He will also serve on the Audit Committee. The board has determined that Farrow qualifies as independent under Nasdaq listing rules.</p> <p>Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS). He also sits on the boards of Clover Biopharmaceuticals, Ltd. (HKEX) and Achieve Life Sciences, Inc. http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html Wed, 14 Oct 2026 16:05:23 -0400 ACHV LSTA TARS http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Equity+Offerings/Tarsus+Pharmaceuticals+%28TARS%29+files+for+up+to+2.91M+share+offering+by+selling+stockholders/27181872.html <p>Tarsus Pharmaceuticals (NASDAQ: TARS) filed for up to 2,908,692 share offering by selling stockholders.</p> http://www.streetinsider.com/Equity+Offerings/Tarsus+Pharmaceuticals+%28TARS%29+files+for+up+to+2.91M+share+offering+by+selling+stockholders/27181872.html Tue, 13 Oct 2026 17:05:16 -0400 TARS http://www.streetinsider.com/Corporate+News/Tarsus+Pharmaceuticals+%28TARS%29+files+for+up+to+2.91M+share+offering+by+selling+stockholders/27181872.html <p>Tarsus Pharmaceuticals (NASDAQ: TARS) filed for up to 2,908,692 share offering by selling stockholders.</p> http://www.streetinsider.com/Corporate+News/Tarsus+Pharmaceuticals+%28TARS%29+files+for+up+to+2.91M+share+offering+by+selling+stockholders/27181872.html Tue, 13 Oct 2026 17:05:16 -0400 TARS http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Tarsus+Pharmaceuticals%2C++++++++++++++/27181852.html si-local-file:///var/storage/secattach/20261013/27181852.html http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Tarsus+Pharmaceuticals%2C++++++++++++++/27181852.html Tue, 13 Oct 2026 17:03:00 -0400 TARS http://www.streetinsider.com/Equity+Offerings/Tarsus+Pharmaceuticals+%28TARS%29+files+for+up+to+2.23M+share+offering+by+selling+stockholders/27181572.html <p>Tarsus Pharmaceuticals (NASDAQ: TARS) filed for up to 2,232,144 share offering by selling stockholders.</p> http://www.streetinsider.com/Equity+Offerings/Tarsus+Pharmaceuticals+%28TARS%29+files+for+up+to+2.23M+share+offering+by+selling+stockholders/27181572.html Tue, 13 Oct 2026 16:32:45 -0400 TARS http://www.streetinsider.com/Corporate+News/Tarsus+Pharmaceuticals+%28TARS%29+files+for+up+to+2.23M+share+offering+by+selling+stockholders/27181572.html <p>Tarsus Pharmaceuticals (NASDAQ: TARS) filed for up to 2,232,144 share offering by selling stockholders.</p> http://www.streetinsider.com/Corporate+News/Tarsus+Pharmaceuticals+%28TARS%29+files+for+up+to+2.23M+share+offering+by+selling+stockholders/27181572.html Tue, 13 Oct 2026 16:32:45 -0400 TARS http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Tarsus+Pharmaceuticals%2C++++++++++++++/27181539.html si-local-file:///var/storage/secattach/20261013/27181539.html http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Tarsus+Pharmaceuticals%2C++++++++++++++/27181539.html Tue, 13 Oct 2026 16:30:00 -0400 TARS http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Tarsus+Pharmaceuticals%2C+++For%3A+Sep+04/27181013.html si-local-file:///var/storage/secattach/20261013/27181013.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Tarsus+Pharmaceuticals%2C+++For%3A+Sep+04/27181013.html Tue, 13 Oct 2026 16:01:00 -0400 TARS http://www.streetinsider.com/Press+Releases/Tarsus+Plans+to+Present+11+Abstracts+Highlighting+New+Insights+in+Demodex+Blepharitis%2C+Ocular+Rosacea+and+the+Real-World+Impact+of+XDEMVY+at+the+American+Academy+of+Optometry+2026+Annual+Meeting/27117979.html <p>IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meeting, taking place Sept. 30–Oct. 3 in Anaheim, California.</p> <p>The planned abstracts provide new insights into the patient burden, diagnosis and treatment of <em>Demodex</em> blepharitis (DB); real-world experiences and outcomes with XDEMVY^® (lotilaner ophthalmic solution) 0.25%; and the prevalence and clinical characteristics of ocular rosacea. Together, the findings are expected to add to a growing body of evidence intended to help eye care professionals better http://www.streetinsider.com/Press+Releases/Tarsus+Plans+to+Present+11+Abstracts+Highlighting+New+Insights+in+Demodex+Blepharitis%2C+Ocular+Rosacea+and+the+Real-World+Impact+of+XDEMVY+at+the+American+Academy+of+Optometry+2026+Annual+Meeting/27117979.html Tue, 29 Sep 2026 08:30:00 -0400 TARS http://www.streetinsider.com/Globe+Newswire/Tarsus+Plans+to+Present+11+Abstracts+Highlighting+New+Insights+in+Demodex+Blepharitis%2C+Ocular+Rosacea+and+the+Real-World+Impact+of+XDEMVY+at+the+American+Academy+of+Optometry+2026+Annual+Meeting/27117979.html <p>IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meeting, taking place Sept. 30–Oct. 3 in Anaheim, California.</p> <p>The planned abstracts provide new insights into the patient burden, diagnosis and treatment of <em>Demodex</em> blepharitis (DB); real-world experiences and outcomes with XDEMVY^® (lotilaner ophthalmic solution) 0.25%; and the prevalence and clinical characteristics of ocular rosacea. Together, the findings are expected to add to a growing body of evidence intended to help eye care professionals better http://www.streetinsider.com/Globe+Newswire/Tarsus+Plans+to+Present+11+Abstracts+Highlighting+New+Insights+in+Demodex+Blepharitis%2C+Ocular+Rosacea+and+the+Real-World+Impact+of+XDEMVY+at+the+American+Academy+of+Optometry+2026+Annual+Meeting/27117979.html Tue, 29 Sep 2026 08:30:00 -0400 TARS http://www.streetinsider.com/New+Coverage/Goldman+Sachs+Assumes+Tarsus+Pharmaceuticals+%28TARS%29+at+Buy/27098114.html (Updated - September 24, 2026 5:38 AM EDT) <p>Goldman Sachs analyst Andrea Newkirk assumes coverage on Tarsus Pharmaceuticals (NASDAQ: TARS) with a Buy rating and a price target of $116.00.</p><p>The analyst comments "TARS is a commercial-stage company developing novel therapies for patients suffering from highly prevalent ophthalmic and dermatological conditions as well as infectious diseases. Lead commercial drug Xdemvy (lotilaner-based eye drop with anti-parasitic properties) is a first-in-class agent for the treatment of Demodex blepharitis (DB; chronic inflammation of the eyelids caused by microscopic Demodex eyelash mites), while gel (TP-04) and oral (TP-05) formulations of lotilaner are being studied in Ph2 http://www.streetinsider.com/New+Coverage/Goldman+Sachs+Assumes+Tarsus+Pharmaceuticals+%28TARS%29+at+Buy/27098114.html Thu, 24 Sep 2026 05:38:34 -0400 TARS http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Assumes+Tarsus+Pharmaceuticals+%28TARS%29+at+Buy/27098114.html (Updated - September 24, 2026 5:38 AM EDT) <p>Goldman Sachs analyst Andrea Newkirk assumes coverage on Tarsus Pharmaceuticals (NASDAQ: TARS) with a Buy rating and a price target of $116.00.</p><p>The analyst comments "TARS is a commercial-stage company developing novel therapies for patients suffering from highly prevalent ophthalmic and dermatological conditions as well as infectious diseases. Lead commercial drug Xdemvy (lotilaner-based eye drop with anti-parasitic properties) is a first-in-class agent for the treatment of Demodex blepharitis (DB; chronic inflammation of the eyelids caused by microscopic Demodex eyelash mites), while gel (TP-04) and oral (TP-05) formulations of lotilaner are being studied in Ph2 http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Assumes+Tarsus+Pharmaceuticals+%28TARS%29+at+Buy/27098114.html Thu, 24 Sep 2026 05:38:34 -0400 TARS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tarsus+Pharmaceuticals%2C+++For%3A+Sep+15++Filed+by%3A+PYOTT+DAVID+E+I/27076527.html si-local-file:///var/storage/secattach/20260917/27076527.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tarsus+Pharmaceuticals%2C+++For%3A+Sep+15++Filed+by%3A+PYOTT+DAVID+E+I/27076527.html Thu, 17 Sep 2026 16:48:00 -0400 TARS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tarsus+Pharmaceuticals%2C+++For%3A+Sep+15++Filed+by%3A+YARNO+WENDY+L/27076167.html si-local-file:///var/storage/secattach/20260917/27076167.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tarsus+Pharmaceuticals%2C+++For%3A+Sep+15++Filed+by%3A+YARNO+WENDY+L/27076167.html Thu, 17 Sep 2026 16:23:00 -0400 TARS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tarsus+Pharmaceuticals%2C+++For%3A+Sep+15++Filed+by%3A+LINK+WILLIAM+J+PHD/27076165.html si-local-file:///var/storage/secattach/20260917/27076165.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tarsus+Pharmaceuticals%2C+++For%3A+Sep+15++Filed+by%3A+LINK+WILLIAM+J+PHD/27076165.html Thu, 17 Sep 2026 16:23:00 -0400 TARS http://www.streetinsider.com/New+Coverage/Barclays+Reinstates+Tarsus+Pharmaceuticals+%28TARS%29+at+Overweight/27066684.html <p>Barclays analyst Glen Santangelo reinstates coverage on Tarsus Pharmaceuticals (NASDAQ: TARS) with a Overweight rating and a price target of $110.00.</p> <p>For an analyst ratings summary and ratings history on Tarsus Pharmaceuticals <a href="http://www.streetinsider.com/rating_history.php?q=TARS">click here</a>. For more ratings news on Tarsus Pharmaceuticals <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TARS&amp;type=analyst">click here</a>.</p> <p>Shares of Tarsus Pharmaceuticals closed at $78.23 yesterday.</p> http://www.streetinsider.com/New+Coverage/Barclays+Reinstates+Tarsus+Pharmaceuticals+%28TARS%29+at+Overweight/27066684.html Wed, 16 Sep 2026 04:45:57 -0400 TARS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Tarsus+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+LINK+WILLIAM+J+PHD/27065545.html si-local-file:///var/storage/secattach/20260915/27065545.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Tarsus+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+LINK+WILLIAM+J+PHD/27065545.html Tue, 15 Sep 2026 16:52:00 -0400 TARS